Fluoropyrimidine

BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China

Retrieved on: 
금요일, 2월 24, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Immunotherapy, Adenocarcinoma, Survival, Stomach, PD-1, Kuwait Cancer Control Center, European Medicines Agency, Sun, PD-L1, Patient, SSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doctor of Philosophy, ITT, National Medical Products Administration, Tislelizumab, GC, EMA, NSCLC, BGNE, Fluoropyrimidine, Neoplasm, Food, NMPA, Pharmaceutical industry, OS, BeiGene

In China, gastric cancer (GC) has become the third most common canceri and adenocarcinoma represents the major histologic subtype, comprising over 90% of reported GC cases across the worldii.

Key Points: 
  • In China, gastric cancer (GC) has become the third most common canceri and adenocarcinoma represents the major histologic subtype, comprising over 90% of reported GC cases across the worldii.
  • More than 70% of patients in China are in advanced or late stage when diagnosediii and the previous standard first-line treatment in China for advanced GC, chemotherapy, provided median overall survival (OS) around one yeariv.
  • Tislelizumab is currently under review by the U.S. Food and Drug Administration and the European Medicines Agency (EMA) for advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy.
  • Tislelizumab is not approved for use outside of China.

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Retrieved on: 
목요일, 10월 13, 2022
Blood, INCA, Dijon, Disease, SEC, Achievement, Neoplasm, Trifluridine/tipiracil, NASDAQ, Irinotecan, The True Cost, Research, Metastasis, Risk, Colorectal cancer, Cancer, Technology, Fluoropyrimidine, Oncology, Trial of the century, National Cancer Institute, Industry, Department, INSERM, Antibody, Safety, GLOBE, Oxaliplatin, Forward-looking statement, Phase, Large intestine, American Cancer Society, Death, Terminology, Pharmaceutical industry, Vaccine

The much anticipated clinical study for XBiotechs candidate cancer treatment is being funded by the French National Cancer Institute (INCA).

Key Points: 
  • The much anticipated clinical study for XBiotechs candidate cancer treatment is being funded by the French National Cancer Institute (INCA).
  • Investigators are combining XBiotechs Natrunix with trifluridine/tipiracil as a new candidate therapy for metastatic colorectal cancer.
  • The study is designed to seamlessly proceed through Phase III development based on achievement of certain efficacy milestones in the Phase I/II portions.
  • Natrunix is a therapeutic monoclonal antibody discovered, manufactured, and undergoing clinical development by XBiotech.

XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Canc

Retrieved on: 
목요일, 4월 28, 2022
Star Trek: Phase II, Metastasis, INCA, INSERM, Purging disorder, Medication, Colorectal cancer, National Agency for Food and Drug Administration and Control, The True Cost, Fatigue, Death, III, Oncology, Patient, Blood, Risk, GLOBE, American Cancer Society, Large intestine, Connective tissue, Cancer, Anxiety, Neoplasm, Technology, Quality of life, Forward-looking statement, Immunohistochemistry, Oxaliplatin, Trifluridine/tipiracil, Fluoropyrimidine, Dijon, Achievement, Antibody, Serum, Research, Terminology, VEGF, NASDAQ, Safety, Phase, Industry, SEC, National Cancer Institute, ANSM, Survival, Disease, Irinotecan, Pharmaceutical industry, Vaccine

The French National Cancer Institute (INCA) has also awarded a grant to fund all clinical costs for the study.

Key Points: 
  • The French National Cancer Institute (INCA) has also awarded a grant to fund all clinical costs for the study.
  • Investigators will combine Natrunix and trifluridine/tipiracil as a new candidate therapy for metastatic colorectal cancer in subjects that have failed earlier treatment with oxaliplatin, irinotecan, and fluoropyrimidine.
  • Headed by Dr. Franois Ghiringhelli and Dr. Come Lepage, the clinical program will include over 20 participating clinical centers and enroll at least 160 subjects.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma

Retrieved on: 
화요일, 4월 5, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, Esophageal cancer, Adenocarcinoma, LinkedIn, Diagnosis, Agilent Technologies, CE, Death, ESCC, Mortality, NYSE, IHC, Survival, Neoplasm, Incidence, Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, Marie Cassidy, Histology, Quality of life, Lead, Software, Twitter, Hope, Matthew 28:8, Squamous cell carcinoma, Union, Solution, Nivolumab, Fluoropyrimidine, News, Bristol Myers Squibb, PD-L1, Patient, Ipilimumab, Pharmaceutical industry, Facebook

The two most common types of esophageal cancer are squamous cell carcinoma and adenocarcinoma, which account for approximately 85% and 15% of all esophageal cancers, respectively, though esophageal tumor histology can vary by region and country.

Key Points: 
  • The two most common types of esophageal cancer are squamous cell carcinoma and adenocarcinoma, which account for approximately 85% and 15% of all esophageal cancers, respectively, though esophageal tumor histology can vary by region and country.
  • PD-L1 is a critical biomarker for response to anti-PD-1 therapies, including the immunotherapeutic agent OPDIVO based on the Phase 3 CheckMate-648 trial results.
  • We greatly value our relationship with Bristol Myers Squibb, and are committed to continuing developing and commercializing market-leading companion diagnostic products.
  • Agilent is the worldwide leader in partnering with pharmaceutical companies to develop IHC-based diagnostics for targeted cancer therapy.